Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840876 | 0.96 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6793526 | 0.80 | CA12 (0.40) | — | |
| SCHEMBL6791153 | 0.76 | MMP2 (0.41) | CYP2C9 | |
| SCHEMBL6789361 | 0.76 | MMP2 (0.41) | CYP2C9 | |
| SCHEMBL6839916 | 0.75 | MMP13 (0.53) | SMN1; SMN2MAPK14ROCK2ROCK1CYP2C9 | |
| SCHEMBL6790247 | 0.75 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2ABRD4HPGD | |
| SCHEMBL6797530 | 0.75 | PRMT5 (0.39) | SMN1; SMN2 | |
| SCHEMBL6798425 | 0.74 | CYP17A1 (0.37) | ROCK2ROCK1 | |
| SCHEMBL6791748 | 0.74 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6791869 | 0.73 | HSD11B1 (0.44) | SMN1; SMN2KMT2AHSD11B1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040110809-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-06-10 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370538-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074752-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110809-A1 | Metalloproteinase inhibitors | MMP9, MMP2, MMP3 | NPC1 1342/4885RAB9A 1922/4885SMN1; SMN2 3091/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | NPC1 150/4885RAB9A 2385/4885SMN1; SMN2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.